The Writing on the Wall
Lancet 372:344, Wilder-Smith,E.P. &Ng,E.S., 2008
Clinicopath Conf., Anti-MNDAR Antibody Mediated Paraneoplastic Limbic Encephalitis Associated With Ovarian Teratoma
NEJM 359:842-853, Case 26-2008, 2008
Anti-NMDA-Receptor Encephalitis: Case Series and Analysis of the Effects of Antibodies
Lancet Neurol 7:1091-1098, Dalmau,J.,et al, 2008
Neuro-Ophthalmologic Manifestations of Paraneoplastic Syndromes
J Neuro-Ophthalmol 28:58-68, Ko,M.W.,et al, 2008
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
Survival after Treatment of Rabies with Induction of Coma
NEJM 352:2508-2514,2549, Willoughby,Jr.,R.E.,et al, 2005
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Memantine in Moderate-to-Severe Alzheimer's Disease
NEJM 348:1333-1341, Reisberg,B.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Clinical Experience with Excitatory Amino Acid Antagonist Drugs
Stroke 26:503-513, Muir,K.W.&Lees,K.R., 1995
The Ischemic Penumbra, Injury Thresholds, and the Therapeutic Window for Acute Stroke
Ann Neurol 36:553-554, 5571994., Ginsberg,M.D.&Pulsinelli,W.A., 1994
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
NEJM 330:613-622, Lipton,S.A.&Rosenberg,P.A., 1994
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? No
Arch Neurol 49:420-421, Buchan,A.M., 1992
N-Methyl-D-Aspartate Antagonists in the Treatment of Parkinson's Disease
Arch Neurol 48:977-981, Greenamyre,J.T.&O'Brien,C.F., 1991
Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991
The Bioloigcal Basis for the Treatment of Acute Stroke
Neurol 41:1867-1873, Scheinberg,P., 1991
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice
Neurol 104:e213498, Zara,P.,et al, 2025
A 56-Year-Old Woman with New-Onset Hoarsement and Dysphagia
Neurol 104:e213363, McAree,M. & Frontera, J.A., 2025
Clinicopathologic Conference, Myasthenia Gravis
NEJM 391:1441-1450, Case 32-2024, 2024
Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease
Ann Neurol 96:1086-1091, Fadda,G.,et al, 2024
Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children
Neurol 103:e209321, Varley,J.A.,et al, 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
MOG-IgG-Associated Encephalitis with FLAIR Hyperintensity Along the Brainstem Surface
Ann Neurol 96:460-462, Yin,J.,et al, 2024
Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology
Ann Neurol 96:1020-1025, Falso,S.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Expanding Clinical Spectrum an Anti-GQ1b Antibody Syndrome, A Review
JAMA Neurol 81:762-770, Lee,S-U.,et al, 2024
MR Imaging Findings in Anti-Leucine-Rich Glioma Inactivated Protein 1 Encephalitis:A Systematic Review and Meta-Analysis
AJNR 45:977-986, Almeida,F.C.,et al, 2024
Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis
Ann Neurol 96:21-33, Gilligan,M.,et al, 2024
Clinicopathologic Conference, Paraneoplastic Encephalomyelitis Due to Small-Cell Lung Carcinoma and Concurrent Cerebral Amyloid Angiopathy
NEJM< 391357-369, Case 23-2024, 2024
Diffusely Enhancing Lesions on MRI in DPPX Antibody-Associated Encephalitis
JAMA Neurol 8:418-419, Liu,M.,et al, 2024
Clinicopatholigic Conference, Rheumatoid Arthritis with Vasculitis Causing A Confluent Mononeuritis Multiplex
NEJM 390:1312-1322, Case 11-2024, 2024
Magnetic Resonance Imaging Characteristics of LGl1-Antibody and CASPR2-Antibody Encephalitis
JAMA Neurol 81:525-533, Kelly,Mark J., et al, 2024
Clinicopathological Conference, Glutamic Acid Decarborylase 65 Autoantibody-Associated Stiff-Person Syndrome
NEJM 390:1712-1719, Case 14-2024, 2024
Recurrent Rhombencephalitis Associatedwith Anti-GAD65 Antibody
Neurol 102:e208040, Alferes,A.R.,et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Posttransplant Anti-GABAA Receptor Antibody-Associated Autoimmune Encephalitis
Neurol 102:e209245, Togni,C.L.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Clinicopathologic Conference, Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis
NEJM 390:843-851, Case 7-2024, 2024
Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023